MarketCap
Facebook
X
Telegram
Athira Pharma Balance Sheet 2025-2011 | ATHA
Brief overview of Athira Pharma's assets and capital
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets finished at $92.2 million versus $332 million initially, losing -72.2%. The balance sheet contracted.
Asset growth of -72.2% came with a +489.2% rise in liabilities. Financial leverage became more prominent.
The equity ratio is 30.2% versus 96.7% five periods ago. Capitalization remains workable.
Negative net debt of -$68.5 million means cash holdings are larger than debt obligations.
Cash equals 75.2% of the balance sheet, compared with 33.3% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$511.8 million. It should be assessed alongside historical profits and capital distributions.
Conclusion
The balance sheet gives no single signal for Athira Pharma: some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet Athira Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-68.5 M | -47.2 M | -89 M | -94.1 M | -109 M | -60.6 M | -503 K | -2.6 M | - | - | - | - | - | - | - |
Long Term Debt |
338 K | 803 K | 1.22 M | 1.58 M | 1.63 M | - | 1.55 M | 722 K | - | - | - | - | - | - | - |
Long Term Debt Current |
465 K | 414 K | 368 K | 326 K | 288 K | 124 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 876 K | 20.6 M | 19.2 M | - | - | - | - | - | - | - |
Total Current Liabilities |
47.5 M | 13.1 M | 28.8 M | 21.4 M | 9.29 M | 4.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
64.4 M | 13.9 M | 30.1 M | 23 M | 10.9 M | 5.28 M | 21.9 M | 19.8 M | - | - | - | - | - | - | - |
Retained Earnings |
-512 M | -406 M | -309 M | -192 M | -95.9 M | - | -21.1 M | -15.9 M | - | - | - | - | - | - | - |
Total Assets |
92.2 M | 58.8 M | 160 M | 258 M | 332 M | 280 M | 2.19 M | 4.93 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
69.3 M | 48.4 M | 90.6 M | 96 M | 111 M | 60.6 M | - | - | - | - | - | - | - | - | - |
Book Value |
27.8 M | 44.8 M | 130 M | 235 M | 321 M | 274 M | -19.7 M | -14.9 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
27.8 M | 44.8 M | 130 M | 235 M | 321 M | 274 M | -19.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Athira Pharma
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
213 K | 460 K | 578 K | 691 K | 803 K | 912 K | 1.02 M | 1.12 M | 1.22 M | 1.31 M | 1.41 M | 1.5 M | 1.58 M | 1.67 M | 1.75 M | 1.55 M | 1.63 M | 1.71 M | 1.78 M | 1.7 M | 876 K | 876 K | 876 K | 876 K | 1.55 M | 1.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
22.3 M | 3.25 M | 3.56 M | 6.18 M | 13.9 M | 28.7 M | 27.9 M | 26.7 M | 30.1 M | 29.9 M | 23.1 M | 21.6 M | 23 M | 11.9 M | 11.4 M | 11 M | 10.9 M | 11.1 M | 9.42 M | 6.2 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 4.86 M | 4.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-545 M | -429 M | -422 M | -415 M | -406 M | -391 M | -362 M | -336 M | -309 M | -282 M | -249 M | -219 M | -192 M | -161 M | -141 M | -117 M | -95.9 M | -79.6 M | -63.9 M | -49.9 M | -41 M | -41 M | -41 M | -41 M | -21.1 M | -21.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
71.6 M | 30 M | 35.5 M | 43.5 M | 58.8 M | 86.2 M | 111 M | 133 M | 160 M | 185 M | 208 M | 233 M | 258 M | 274 M | 292 M | 313 M | 332 M | 347 M | 360 M | 369 M | 280 M | 280 M | 280 M | 280 M | 2.19 M | 2.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
32.8 M | 20.9 M | 19.9 M | 26.4 M | 48.4 M | 68.9 M | 73.8 M | 77.8 M | 90.6 M | 110 M | 114 M | 105 M | 96 M | 87 M | 95.1 M | 118 M | 111 M | 107 M | 132 M | 128 M | 60.6 M | 60.6 M | 60.6 M | 60.6 M | 2.06 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
49.3 M | 26.8 M | 32 M | 37.3 M | 44.8 M | 57.6 M | 83.3 M | 107 M | 130 M | 155 M | 185 M | 211 M | 235 M | 262 M | 281 M | 302 M | 321 M | 336 M | 351 M | 363 M | 274 M | 274 M | 274 M | 274 M | -2.67 M | -2.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
49.3 M | 26.8 M | 32 M | 37.3 M | 44.8 M | 57.6 M | 83.3 M | 107 M | 130 M | 155 M | 185 M | 211 M | 235 M | 262 M | 281 M | 302 M | 321 M | 336 M | 351 M | 363 M | 274 M | 274 M | 274 M | 274 M | -19.7 M | -19.7 M | -17.4 M | - | -14.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Athira Pharma, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
